Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion_老虎社区_美港股上老虎

Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion

Bloomberg2021-08-23

Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion. Pfizer...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

RO8
·2021-08-25
Good buy good buy
回复
1
举报
Mml
·2021-08-24
Informative
回复
3
举报
Lhgoh
·2021-08-23
Not bad
回复
3
举报
收起
- huilly:
  wow..
  2021-08-23
  回复
  举报
- JackTL:
  is good news
  2021-08-23
  回复
  举报
HENRYCSC
·2021-08-23
Advance
回复
2
举报
Gummybear
·2021-08-23
Power
回复
3
举报
Sriwonc
·2021-08-23
Like
回复
3
举报
收起
- K20:
  like
  2021-08-23
  回复
  举报
jyt20275
·2021-08-23
Good news
回复
3
举报
Horsesaylah
·2021-08-23
🙏🏻
回复
3
举报
KenT
·2021-08-23
D
回复
4
举报
Blitzery
·2021-08-23
I pray that the cost of cancer treatment will be more affordable and effective with the direction of this news please 🙏
回复
7
举报
jktrade
·2021-08-23
Hmm...
回复
5
举报
PhilipGoh
·2021-08-23
Good
回复
3
举报
jingabel
·2021-08-23
Ok
回复
2
举报
Yappydappy
·2021-08-23
Is it going to soar now?
回复
2
举报
收起
- SARA_231:
  yes!
  2021-08-23
  回复
  举报
Korimerla
·2021-08-23
Noted
回复
2
举报
收起
- Korimerla:
  ok
  2021-08-23
  回复
  举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1140755633?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-08-23 19:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1140755633","market":"us","top_or_hot":-1,"title":"Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion","media":"Bloomberg","content":"<div>\n<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp\">网页链接</a>\n\n</div>\n","source":"lsy1584095487587","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-23 19:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PFE","symbol_name":"辉瑞","start_time":0,"source_url":"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp","article_id":"1140755633","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1140755633","pubTimestamp":1629717900,"sourceInfo":{"source_id":"lsy1584095487587","name":"Bloomberg"},"weMediaInfo":null,"summary":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics ","collect":0,"end_time":0,"defaultTopTitle":"bloomberg.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PFE":"辉瑞","TRIL":"Trillium Therapeutics Inc."},"translate_title":"辉瑞将以23亿美元收购癌症制药商延龄草","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":0.9,"TRIL":0.9},"content_text":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a statement. The price represents a 118% premium to the stock’s 60-day weighted average price.\nPfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.\nTrillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.\nShares of Trillium nearly tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":837000432,"gmtCreate":1629845584626,"gmtModify":1631893493323,"author":{"id":"3585981947031986","authorId":"3585981947031986","name":"RO8","avatar":"https://static.tigerbbs.com/1f744cb66900b3865c3ed1da7364ddce","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3585981947031986","authorIdStr":"3585981947031986"},"htmlText":"Good buy good buy","listText":"Good buy good buy","text":"Good buy good buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/837000432","repostId":1140755633,"repostType":4,"repost":{"id":"1140755633","pubTimestamp":1629717900,"share":"https://www.laohu8.com/m/news/1140755633?lang=&edition=full","pubTime":"2021-08-23 19:25","market":"us","language":"en","title":"Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1140755633","media":"Bloomberg","summary":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics ","content":"<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of&nbsp;Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.</p>\n<p>Pfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a&nbsp;statement. The price represents a 118% premium to the stock’s 60-day weighted average price.</p>\n<p>Pfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.</p>\n<p>Trillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.</p>\n<p>Shares of Trillium nearly&nbsp;tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-23 19:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRIL":"Trillium Therapeutics Inc.","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140755633","content_text":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a statement. The price represents a 118% premium to the stock’s 60-day weighted average price.\nPfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.\nTrillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.\nShares of Trillium nearly tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":834237694,"gmtCreate":1629805615318,"gmtModify":1633682330153,"author":{"id":"3584863771682470","authorId":"3584863771682470","name":"Mml","avatar":"https://static.tigerbbs.com/f24c9f80edf3964f1c5ee7b551e05463","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3584863771682470","authorIdStr":"3584863771682470"},"htmlText":"Informative&nbsp;","listText":"Informative&nbsp;","text":"Informative","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/834237694","repostId":1140755633,"repostType":4,"repost":{"id":"1140755633","pubTimestamp":1629717900,"share":"https://www.laohu8.com/m/news/1140755633?lang=&edition=full","pubTime":"2021-08-23 19:25","market":"us","language":"en","title":"Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1140755633","media":"Bloomberg","summary":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics ","content":"<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of&nbsp;Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.</p>\n<p>Pfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a&nbsp;statement. The price represents a 118% premium to the stock’s 60-day weighted average price.</p>\n<p>Pfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.</p>\n<p>Trillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.</p>\n<p>Shares of Trillium nearly&nbsp;tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-23 19:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRIL":"Trillium Therapeutics Inc.","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140755633","content_text":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a statement. The price represents a 118% premium to the stock’s 60-day weighted average price.\nPfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.\nTrillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.\nShares of Trillium nearly tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":835261682,"gmtCreate":1629721420846,"gmtModify":1633682960681,"author":{"id":"3583662534350147","authorId":"3583662534350147","name":"Lhgoh","avatar":"https://static.tigerbbs.com/1c2aee9a5977b03cf1fb62e2691c9aee","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3583662534350147","authorIdStr":"3583662534350147"},"htmlText":"Not bad","listText":"Not bad","text":"Not bad","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/835261682","repostId":1140755633,"repostType":4,"repost":{"id":"1140755633","pubTimestamp":1629717900,"share":"https://www.laohu8.com/m/news/1140755633?lang=&edition=full","pubTime":"2021-08-23 19:25","market":"us","language":"en","title":"Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1140755633","media":"Bloomberg","summary":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics ","content":"<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of&nbsp;Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.</p>\n<p>Pfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a&nbsp;statement. The price represents a 118% premium to the stock’s 60-day weighted average price.</p>\n<p>Pfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.</p>\n<p>Trillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.</p>\n<p>Shares of Trillium nearly&nbsp;tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-23 19:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRIL":"Trillium Therapeutics Inc.","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140755633","content_text":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a statement. The price represents a 118% premium to the stock’s 60-day weighted average price.\nPfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.\nTrillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.\nShares of Trillium nearly tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5622090,"gmtCreate":1629723993951,"gmtModify":1631896731624,"authorId":3584235357352543,"author":{"id":3584235357352543,"idStr":"3584235357352543","authorId":3584235357352543,"name":"huilly","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":835261682,"type":1,"supId":5621953,"prevId":0,"content":"wow..","text":"wow..","html":"wow.."},{"id":5621953,"gmtCreate":1629723197658,"gmtModify":1631896731615,"authorId":3581557493426416,"author":{"id":3581557493426416,"idStr":"3581557493426416","authorId":3581557493426416,"name":"JackTL","avatar":"https://static.tigerbbs.com/851801800e7dc3457e5e60048a987880","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":835261682,"type":1,"supId":0,"prevId":0,"content":"is good news","text":"is good news","html":"is good news"}],"langContent":"EN"},{"id":835263352,"gmtCreate":1629721296076,"gmtModify":1633682961692,"author":{"id":"3575091428590185","authorId":"3575091428590185","name":"HENRYCSC","avatar":"https://static.tigerbbs.com/6d47a6dec25b21dc547a5b982674c499","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3575091428590185","authorIdStr":"3575091428590185"},"htmlText":"Advance&nbsp;","listText":"Advance&nbsp;","text":"Advance","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/835263352","repostId":1140755633,"repostType":4,"repost":{"id":"1140755633","pubTimestamp":1629717900,"share":"https://www.laohu8.com/m/news/1140755633?lang=&edition=full","pubTime":"2021-08-23 19:25","market":"us","language":"en","title":"Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1140755633","media":"Bloomberg","summary":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics ","content":"<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of&nbsp;Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.</p>\n<p>Pfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a&nbsp;statement. The price represents a 118% premium to the stock’s 60-day weighted average price.</p>\n<p>Pfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.</p>\n<p>Trillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.</p>\n<p>Shares of Trillium nearly&nbsp;tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-23 19:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRIL":"Trillium Therapeutics Inc.","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140755633","content_text":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a statement. The price represents a 118% premium to the stock’s 60-day weighted average price.\nPfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.\nTrillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.\nShares of Trillium nearly tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":835287126,"gmtCreate":1629720998865,"gmtModify":1631888657670,"author":{"id":"3581807556130510","authorId":"3581807556130510","name":"Gummybear","avatar":"https://static.tigerbbs.com/d2911351e3538d3ec7f08d283fb4ccfe","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581807556130510","authorIdStr":"3581807556130510"},"htmlText":"Power","listText":"Power","text":"Power","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/835287126","repostId":1140755633,"repostType":4,"repost":{"id":"1140755633","pubTimestamp":1629717900,"share":"https://www.laohu8.com/m/news/1140755633?lang=&edition=full","pubTime":"2021-08-23 19:25","market":"us","language":"en","title":"Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1140755633","media":"Bloomberg","summary":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics ","content":"<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of&nbsp;Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.</p>\n<p>Pfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a&nbsp;statement. The price represents a 118% premium to the stock’s 60-day weighted average price.</p>\n<p>Pfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.</p>\n<p>Trillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.</p>\n<p>Shares of Trillium nearly&nbsp;tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-23 19:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRIL":"Trillium Therapeutics Inc.","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140755633","content_text":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a statement. The price represents a 118% premium to the stock’s 60-day weighted average price.\nPfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.\nTrillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.\nShares of Trillium nearly tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":835212270,"gmtCreate":1629720201790,"gmtModify":1633682971972,"author":{"id":"3586424409701165","authorId":"3586424409701165","name":"Sriwonc","avatar":"https://static.tigerbbs.com/264a5cfcdc2db585d9b139a4c4d7b11d","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3586424409701165","authorIdStr":"3586424409701165"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/835212270","repostId":1140755633,"repostType":4,"repost":{"id":"1140755633","pubTimestamp":1629717900,"share":"https://www.laohu8.com/m/news/1140755633?lang=&edition=full","pubTime":"2021-08-23 19:25","market":"us","language":"en","title":"Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1140755633","media":"Bloomberg","summary":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics ","content":"<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of&nbsp;Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.</p>\n<p>Pfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a&nbsp;statement. The price represents a 118% premium to the stock’s 60-day weighted average price.</p>\n<p>Pfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.</p>\n<p>Trillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.</p>\n<p>Shares of Trillium nearly&nbsp;tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-23 19:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRIL":"Trillium Therapeutics Inc.","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140755633","content_text":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a statement. The price represents a 118% premium to the stock’s 60-day weighted average price.\nPfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.\nTrillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.\nShares of Trillium nearly tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5622079,"gmtCreate":1629723914574,"gmtModify":1635144509988,"authorId":3583284147557843,"author":{"id":3583284147557843,"idStr":"3583284147557843","authorId":3583284147557843,"name":"K20","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":835212270,"type":1,"supId":0,"prevId":0,"content":"like","text":"like","html":"like"}],"langContent":"EN"},{"id":835232898,"gmtCreate":1629719550714,"gmtModify":1633682978761,"author":{"id":"3581983450078020","authorId":"3581983450078020","name":"jyt20275","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581983450078020","authorIdStr":"3581983450078020"},"htmlText":"Good news","listText":"Good news","text":"Good news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/835232898","repostId":1140755633,"repostType":4,"repost":{"id":"1140755633","pubTimestamp":1629717900,"share":"https://www.laohu8.com/m/news/1140755633?lang=&edition=full","pubTime":"2021-08-23 19:25","market":"us","language":"en","title":"Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1140755633","media":"Bloomberg","summary":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics ","content":"<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of&nbsp;Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.</p>\n<p>Pfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a&nbsp;statement. The price represents a 118% premium to the stock’s 60-day weighted average price.</p>\n<p>Pfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.</p>\n<p>Trillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.</p>\n<p>Shares of Trillium nearly&nbsp;tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-23 19:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRIL":"Trillium Therapeutics Inc.","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140755633","content_text":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a statement. The price represents a 118% premium to the stock’s 60-day weighted average price.\nPfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.\nTrillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.\nShares of Trillium nearly tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":835230223,"gmtCreate":1629718952062,"gmtModify":1631891560725,"author":{"id":"3570240810344953","authorId":"3570240810344953","name":"Horsesaylah","avatar":"https://static.tigerbbs.com/7a32990d23360f1c603728cf63a7ec50","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3570240810344953","authorIdStr":"3570240810344953"},"htmlText":"🙏🏻","listText":"🙏🏻","text":"🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/835230223","repostId":1140755633,"repostType":4,"repost":{"id":"1140755633","pubTimestamp":1629717900,"share":"https://www.laohu8.com/m/news/1140755633?lang=&edition=full","pubTime":"2021-08-23 19:25","market":"us","language":"en","title":"Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1140755633","media":"Bloomberg","summary":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics ","content":"<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of&nbsp;Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.</p>\n<p>Pfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a&nbsp;statement. The price represents a 118% premium to the stock’s 60-day weighted average price.</p>\n<p>Pfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.</p>\n<p>Trillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.</p>\n<p>Shares of Trillium nearly&nbsp;tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-23 19:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRIL":"Trillium Therapeutics Inc.","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140755633","content_text":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a statement. The price represents a 118% premium to the stock’s 60-day weighted average price.\nPfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.\nTrillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.\nShares of Trillium nearly tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":835296482,"gmtCreate":1629718507446,"gmtModify":1633682983680,"author":{"id":"3580341419226466","authorId":"3580341419226466","name":"KenT","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3580341419226466","authorIdStr":"3580341419226466"},"htmlText":"D","listText":"D","text":"D","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/835296482","repostId":1140755633,"repostType":4,"repost":{"id":"1140755633","pubTimestamp":1629717900,"share":"https://www.laohu8.com/m/news/1140755633?lang=&edition=full","pubTime":"2021-08-23 19:25","market":"us","language":"en","title":"Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1140755633","media":"Bloomberg","summary":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics ","content":"<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of&nbsp;Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.</p>\n<p>Pfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a&nbsp;statement. The price represents a 118% premium to the stock’s 60-day weighted average price.</p>\n<p>Pfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.</p>\n<p>Trillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.</p>\n<p>Shares of Trillium nearly&nbsp;tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-23 19:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRIL":"Trillium Therapeutics Inc.","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140755633","content_text":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a statement. The price represents a 118% premium to the stock’s 60-day weighted average price.\nPfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.\nTrillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.\nShares of Trillium nearly tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":835298654,"gmtCreate":1629718368778,"gmtModify":1631890160453,"author":{"id":"3578091555231876","authorId":"3578091555231876","name":"Blitzery","avatar":"https://static.tigerbbs.com/bac6c599695ac8c073cc33419fb12a9b","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"3578091555231876","authorIdStr":"3578091555231876"},"htmlText":"I pray that the cost of cancer treatment will be more affordable and effective with the direction of this news please 🙏","listText":"I pray that the cost of cancer treatment will be more affordable and effective with the direction of this news please 🙏","text":"I pray that the cost of cancer treatment will be more affordable and effective with the direction of this news please 🙏","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/835298654","repostId":1140755633,"repostType":4,"repost":{"id":"1140755633","pubTimestamp":1629717900,"share":"https://www.laohu8.com/m/news/1140755633?lang=&edition=full","pubTime":"2021-08-23 19:25","market":"us","language":"en","title":"Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1140755633","media":"Bloomberg","summary":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics ","content":"<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of&nbsp;Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.</p>\n<p>Pfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a&nbsp;statement. The price represents a 118% premium to the stock’s 60-day weighted average price.</p>\n<p>Pfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.</p>\n<p>Trillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.</p>\n<p>Shares of Trillium nearly&nbsp;tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-23 19:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRIL":"Trillium Therapeutics Inc.","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140755633","content_text":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a statement. The price represents a 118% premium to the stock’s 60-day weighted average price.\nPfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.\nTrillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.\nShares of Trillium nearly tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":835298374,"gmtCreate":1629718353598,"gmtModify":1633682984958,"author":{"id":"4087905137947130","authorId":"4087905137947130","name":"jktrade","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"4087905137947130","authorIdStr":"4087905137947130"},"htmlText":"Hmm...","listText":"Hmm...","text":"Hmm...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/835298374","repostId":1140755633,"repostType":4,"repost":{"id":"1140755633","pubTimestamp":1629717900,"share":"https://www.laohu8.com/m/news/1140755633?lang=&edition=full","pubTime":"2021-08-23 19:25","market":"us","language":"en","title":"Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1140755633","media":"Bloomberg","summary":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics ","content":"<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of&nbsp;Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.</p>\n<p>Pfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a&nbsp;statement. The price represents a 118% premium to the stock’s 60-day weighted average price.</p>\n<p>Pfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.</p>\n<p>Trillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.</p>\n<p>Shares of Trillium nearly&nbsp;tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-23 19:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRIL":"Trillium Therapeutics Inc.","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140755633","content_text":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a statement. The price represents a 118% premium to the stock’s 60-day weighted average price.\nPfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.\nTrillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.\nShares of Trillium nearly tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":835293459,"gmtCreate":1629718229871,"gmtModify":1633682986087,"author":{"id":"3574730309796268","authorId":"3574730309796268","name":"PhilipGoh","avatar":"https://static.tigerbbs.com/d6085185a57dcb9a222e871338387428","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"3574730309796268","authorIdStr":"3574730309796268"},"htmlText":"Good&nbsp;","listText":"Good&nbsp;","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/835293459","repostId":1140755633,"repostType":4,"repost":{"id":"1140755633","pubTimestamp":1629717900,"share":"https://www.laohu8.com/m/news/1140755633?lang=&edition=full","pubTime":"2021-08-23 19:25","market":"us","language":"en","title":"Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1140755633","media":"Bloomberg","summary":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics ","content":"<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of&nbsp;Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.</p>\n<p>Pfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a&nbsp;statement. The price represents a 118% premium to the stock’s 60-day weighted average price.</p>\n<p>Pfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.</p>\n<p>Trillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.</p>\n<p>Shares of Trillium nearly&nbsp;tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-23 19:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRIL":"Trillium Therapeutics Inc.","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140755633","content_text":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a statement. The price represents a 118% premium to the stock’s 60-day weighted average price.\nPfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.\nTrillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.\nShares of Trillium nearly tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":835299645,"gmtCreate":1629718068387,"gmtModify":1631892156010,"author":{"id":"3579683280519440","authorId":"3579683280519440","name":"jingabel","avatar":"https://static.tigerbbs.com/5109716c64f0b691a5098e4d5397ffc2","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3579683280519440","authorIdStr":"3579683280519440"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/835299645","repostId":1140755633,"repostType":4,"repost":{"id":"1140755633","pubTimestamp":1629717900,"share":"https://www.laohu8.com/m/news/1140755633?lang=&edition=full","pubTime":"2021-08-23 19:25","market":"us","language":"en","title":"Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1140755633","media":"Bloomberg","summary":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics ","content":"<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of&nbsp;Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.</p>\n<p>Pfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a&nbsp;statement. The price represents a 118% premium to the stock’s 60-day weighted average price.</p>\n<p>Pfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.</p>\n<p>Trillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.</p>\n<p>Shares of Trillium nearly&nbsp;tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-23 19:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRIL":"Trillium Therapeutics Inc.","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140755633","content_text":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a statement. The price represents a 118% premium to the stock’s 60-day weighted average price.\nPfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.\nTrillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.\nShares of Trillium nearly tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":835290765,"gmtCreate":1629717995257,"gmtModify":1631891023523,"author":{"id":"3579410204959880","authorId":"3579410204959880","name":"Yappydappy","avatar":"https://static.tigerbbs.com/5b6252f503d56d09093797f9e318ebf9","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3579410204959880","authorIdStr":"3579410204959880"},"htmlText":"Is it going to soar now?&nbsp;","listText":"Is it going to soar now?&nbsp;","text":"Is it going to soar now?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/835290765","repostId":1140755633,"repostType":4,"repost":{"id":"1140755633","pubTimestamp":1629717900,"share":"https://www.laohu8.com/m/news/1140755633?lang=&edition=full","pubTime":"2021-08-23 19:25","market":"us","language":"en","title":"Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1140755633","media":"Bloomberg","summary":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics ","content":"<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of&nbsp;Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.</p>\n<p>Pfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a&nbsp;statement. The price represents a 118% premium to the stock’s 60-day weighted average price.</p>\n<p>Pfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.</p>\n<p>Trillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.</p>\n<p>Shares of Trillium nearly&nbsp;tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-23 19:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRIL":"Trillium Therapeutics Inc.","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140755633","content_text":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a statement. The price represents a 118% premium to the stock’s 60-day weighted average price.\nPfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.\nTrillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.\nShares of Trillium nearly tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5621097,"gmtCreate":1629718820427,"gmtModify":1631891023545,"authorId":3582880272972541,"author":{"id":3582880272972541,"idStr":"3582880272972541","authorId":3582880272972541,"name":"SARA_231","avatar":"https://static.tigerbbs.com/bd8d92b2f3729a7b1cddcc2e989397cc","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":835290765,"type":1,"supId":0,"prevId":0,"content":"yes!","text":"yes!","html":"yes!"}],"langContent":"EN"},{"id":835290832,"gmtCreate":1629717973726,"gmtModify":1633682987321,"author":{"id":"3566099162047280","authorId":"3566099162047280","name":"Korimerla","avatar":"https://static.tigerbbs.com/8b1e7ef47aacafc432f0fe3719112ea2","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3566099162047280","authorIdStr":"3566099162047280"},"htmlText":"Noted&nbsp;","listText":"Noted&nbsp;","text":"Noted","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/835290832","repostId":1140755633,"repostType":4,"repost":{"id":"1140755633","pubTimestamp":1629717900,"share":"https://www.laohu8.com/m/news/1140755633?lang=&edition=full","pubTime":"2021-08-23 19:25","market":"us","language":"en","title":"Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1140755633","media":"Bloomberg","summary":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics ","content":"<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of&nbsp;Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.</p>\n<p>Pfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a&nbsp;statement. The price represents a 118% premium to the stock’s 60-day weighted average price.</p>\n<p>Pfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.</p>\n<p>Trillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.</p>\n<p>Shares of Trillium nearly&nbsp;tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer to Acquire Cancer Drugmaker Trillium for $2.3 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-23 19:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TRIL":"Trillium Therapeutics Inc.","PFE":"辉瑞"},"source_url":"https://www.bloomberg.com/news/articles/2021-08-23/pfizer-to-acquire-cancer-drugmaker-trillium-for-2-3-billion?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140755633","content_text":"Pfizer Inc., maker of a top-selling Covid vaccine, will buy all the shares of Trillium Therapeutics Inc.it doesn’t own, gaining the immune cancer drugmaker for an equity value of $2.26 billion.\nPfizer will pay $18.50 a share for Cambridge, Massachusetts-based Trillium, the companies said Monday in a statement. The price represents a 118% premium to the stock’s 60-day weighted average price.\nPfizer invested $25 million in Trillium in September as part of its Breakthrough Growth Initiative, when Jeff Settleman, senior vice president of Pfizer’s oncology research and development group, was named to Trillium’s scientific advisory board.\nTrillium’s two lead molecules, TTI-622 and TTI-621, block signaling proteins involved in blood cancers, and are both in human trials across several types of disease.\nShares of Trillium nearly tripled in trading before U.S. markets opened, while Pfizer rose 3.8%.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5620968,"gmtCreate":1629717983042,"gmtModify":1635144593609,"authorId":3566099162047280,"author":{"id":3566099162047280,"idStr":"3566099162047280","authorId":3566099162047280,"name":"Korimerla","avatar":"https://static.tigerbbs.com/8b1e7ef47aacafc432f0fe3719112ea2","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":835290832,"type":1,"supId":0,"prevId":0,"content":"ok<br>","text":"ok<br>","html":"ok<br>"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":99,"commentSize":15,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}